Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PGNX

Progenics Pharmaceuticals (PGNX) Stock Price, News & Analysis

Progenics Pharmaceuticals logo

About Progenics Pharmaceuticals Stock (NASDAQ:PGNX)

Advanced Chart

Key Stats

Today's Range
$3.94
$4.79
50-Day Range
$4.10
$4.10
52-Week Range
$1.89
$6.37
Volume
34.93 million shs
Average Volume
1.16 million shs
Market Capitalization
$355.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progenics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PGNX Stock News Headlines

PGNX_old Historical Data
Investing in Pharmaceutical Stocks
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
I've Got an Options Bandage for a Sick Economy
See More Headlines

PGNX Stock Analysis - Frequently Asked Questions

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.03. The biotechnology company had revenue of $6.25 million for the quarter. Progenics Pharmaceuticals had a negative net margin of 180.28% and a negative trailing twelve-month return on equity of 129.46%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Progenics Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Caterpillar (CAT), Exelixis (EXEL), IMAX (IMAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Citius Pharmaceuticals (CTXR).

Company Calendar

Last Earnings
5/07/2020
Today
7/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PGNX
CIK
835887
Fax
N/A
Employees
79
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.55 million
Net Margins
-180.28%
Pretax Margin
N/A
Return on Equity
-129.46%
Return on Assets
-53.23%

Debt

Debt-to-Equity Ratio
0.99
Current Ratio
2.12
Quick Ratio
2.12

Sales & Book Value

Annual Sales
$34.99 million
Price / Sales
10.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
7.59

Miscellaneous

Outstanding Shares
86,597,000
Free Float
N/A
Market Cap
$355.05 million
Optionable
Optionable
Beta
1.89
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:PGNX) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners